Table I.

µCT analysis of trabecular bone in male placebo (vehicle)- and etidronate-treated Enpp1^−/− and WT mice.

	WT		Enpp1−/−
	Placebo	Etidronate	Placebo	Etidronate
BV/TV (%)	8.79±1.59	8.75±1.79	3.39±1.06a,e	4.63±1.57a,e
BMD (g/cm3)	0.139±0.021	0.13±0.024	0.042±0.020a,e	0.062±0.025a,e
Tb.Th (µm)	60.62±4.31	57.34±8.34	48.35±3.08a,e	47.99±3.54a,d
Tb.Sp (µm)	298.24±12.68	290.47±26.56	363.66±48.07a,d	319.66±48.44b,c
Tb.N	0.00146±0.00023	0.0015±0.00029	0.00070±0.00024a,e	0.00097±0.00034a,e
Tb.Pf	0.027±0.0026	0.026±0.0033	0.042±0.0036a,e	0.0392±0.0053a,e
SMI	2.48±0.11	2.33±0.23	2.78±0.093a,d	2.69±0.22a,e
DA	2.30±0.19	2.08±0.15	2.42±0.28	2.39±0.31a,c

Results are expressed as the means ± SEM.

^aSignificant difference compared to wild-type (WT) mice;

^bsignificant difference compared to placebo-treated mice.

^cP<0.05;

^dP<0.01;

^eP<0.001. µCT, micro-computed tomography; BV/TV, bone volume/trabecular bone volume; BMD, bone mineral density; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Tb.N, trabecular number; Tb.Pf, trabecular patten factor; SMI, structure model index; DA, degree of anisotropy.